Table 3.
The associations of SIRT1 overexpression with the clinicopathological characteristics of the study patients.
| Clinicopathological parameters | No. of trials (patients) | RR (95%CI) Fixed-effect estimate | P-value of Fixed-effect Model | RR (95%CI) Random-effect estimate | P-value of Random-effect Model | Heterogeneity I2(%), P-value | P-value of Egger's test, Begg's test |
|---|---|---|---|---|---|---|---|
| Tumor stage | 33 (5857) | 1.133 (1.062–1.209) | 0.0002 | 1.299 (1.114–1.514) | 0.0008 | 77.4%, < 0.0001 | 0.0070, 0.1827 |
| Lymphatic metastasis | 29 (6354) | 1.046 (0.995–1.100) | 0.0763 | 1.172 (1.010–1.360) | 0.0363 | 86.3%, < 0.0001 | 0.0637, 0.4308 |
| Distant metastasis | 14 (2632) | 1.607 (1.312–1.968) | < 0.0001 | 1.562 (1.022–2.387) | 0.0392 | 71.0%, < 0.0001 | 0.6780, 0.3520 |
| Tumor size | 21 (2469) | 1.143 (1.050–1.245) | 0.0021 | 1.101 (0.984–1.232) | 0.0924 | 41.7%, 0.0241 | 0.1660, 0.2047 |
| Depth of tumor invasion | 19 (4689) | 1.036 (0.982–1.093) | 0.1912 | 1.113 (0.985–1.258) | 0.0852 | 81.70%, < 0.0001 | 0.0903, 0.1955 |
| Differentiation | 28 (5740) | 1.010 (0.940–1.085) | 0.7841 | 1.055 (0.931–1.196) | 0.3996 | 63.10%, < 0.0001 | 0.1170, 0.3847 |
| Age | 38 (7223) | 1.052 (1.004–1.102) | 0.0345 | 1.043 (0.973–1.118) | 0.2373 | 43.50%, 0.0027 | 0.5651, 0.8308 |
| Gender | 34 (6129) | 1.003 (0.967–1.040) | 0.8739 | 0.991 (0.950–1.035) | 0.6858 | 35.00%, 0.0247 | 0.1727, 0.3353 |
RR, relative risk; CI, confidence interval; I2, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity; Egger's test, P-value of Egger's regression for asymmetry assessment; Begg's test: P-value of Begg and Mazumdar rank correlation test for asymmetry assessment. Bold italics indicate statistically significant values (P < 0.05).